+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Exosome Development and Manufacturing Services Market, 2022-2035

  • PDF Icon

    Report

  • 209 Pages
  • February 2022
  • Region: Global
  • Roots Analysis
  • ID: 5557816
Exosomes are extracellular vesicles that play an important role in cell-to-cell communication and act as carriers of circulating nucleic acids, lipids and proteins in body. Over time, various research studies have demonstrated the potential of exosomes in disease diagnosis and drug delivery applications, owing to their ability to act as biomarkers for various diseases and transport important functional elements. Given the various benefits, exosomes have gained significant interest in the biopharmaceutical industry, likely to result in their increased demand. However, the development and manufacturing of exosomes is associated with several challenges, including lack of standardized isolation and purification methods, limited drug loading ability, and inadequate clinical grade production and GMP compliant industrial scale-up. Therefore, outsourcing of exosome development and manufacturing is seen as a preferable option by companies focused on development of exosome based diagnostics and therapeutics.

Presently, several companies offer services for exosome development and manufacturing. The primary benefit of engaging service providers is to overcome various challenges related to exosome development, such as heterogeneity of exosomes, optimization of exosome isolation, purification and characterization methods and lack of specific biomarkers. Further, in order to leverage the full potential of exosomes, advanced exosome technologies are being developed to fully substructure their therapeutic applications. In addition, extensive research is being conducted to develop methods for extraction of exosomes with high level of purity and sensitivity. The growth in research over the last few years is evident from the published scientific literature and the clinical trial activity in this domain. The market has also witnessed substantial partnership activity, including several technology licensing deals. Moreover, the service providers are actively upgrading their capabilities and infrastructure to accommodate the current and anticipated demand for these extracellular vesicles. Driven by the ongoing research activity, technological advancements and efforts of the players offering exosome development and manufacturing services, the market is poised to witness healthy growth over the next decade.


Scope of the Report



The “Exosome Development and Manufacturing Services Market by Scale of Operation (Discovery / Research, Preclinical and Clinical) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2022-2035” report features an extensive study on the current market landscape, offering an informed opinion on the likely future potential of exosome service providers over the next decade. The study underlines an in-depth analysis, highlighting the diverse capabilities of various industry stakeholders engaged in this field. 


In addition to other elements, the report includes:


  • A detailed assessment of the current market landscape of exosome service providers along with the information on their year of establishment, company size, location of headquarters, types of service(s) offered (isolation, characterization, purification, chromatography, engineering, targeted delivery, diagnostic biomarker, and quality control), method of isolation, method of purification, method of characterization, method of exosome manufacturing (engineering and targeted delivery), scale of operation (discovery / research, pre-clinical, clinical or commercialized) and scalability (small, mid-sized or large).
  • A competitiveness analysis of exosome service providers based on various relevant parameters, such as supplier strength (based on the experience / expertise of the service providers and company size), service strength (number of stages of development (discovery, preclinical, clinical or commercialized), scalability criteria, number of isolation and purification methods, number of characterization methods, number of chromatography techniques, quality control methods and exosome manufacturing methods).
  • Detailed profiles of prominent exosome service providers. Each company profile features a brief overview of the company, its financial information (if available), details on its exosome service portfolio, recent developments and an informed future outlook.
  • An analysis of the partnerships that have been established in this domain since 2016, covering R&D agreements, research, development and commercialization collaborations, product development agreements, mergers and acquisitions, product development and commercialization agreements, distribution / supply agreements, licensing deals, asset acquisitions, and clinical trial agreements. 
  • A detailed review of 6,451 peer-reviewed, scientific articles related to research on exosomes on the basis of several relevant parameters, such as year of publication, type of service(s) offered, emerging focus areas. The chapter also highlights the top journals (in terms of number of articles published and impact factor).
  • A detailed analysis of the global events attended by the participants, based on several relevant parameters, such as year of event, type of event platform, location of event, emerging focus areas, active organizers (in terms of number of events), active industry and non-industry participants, designation of participants, affiliated department of participant, active speakers (in terms of number of events). The chapter also highlights the geographical mapping of upcoming events.
  • An overview of the landscape of exosome-based technologies, featuring analyses of various technology providers, based on several relevant parameters, such as year of establishment, company size and location of headquarters.
  • An insightful analysis of the patents filed / granted for exosome technologies, during the period between 2016 and 2021 (till November), taking into consideration several relevant parameters, such as type of patent, publication year, application year, geographical location, Cooperative Patent Classification (CPC) symbols, emerging focus areas, leading industry and non-industry players (on the basis of number of patents) and individual patent assignees (in terms of size of intellectual property portfolio), patent benchmarking, patent characteristics and age of patents. The chapter also includes an insightful valuation analysis.
  • A detailed analysis of completed and ongoing clinical trials of exosomes, based on different parameters, such as trial status, trial registration year, trial registration year and enrolled patient population, trial recruitment status, trial phase and number of patients enrolled, study design, type pf sponsor / collaborator, leading players (on basis of number of registered trials),emerging focus areas and location of the trials (on basis of number of registered trials and enrolled patient population).
One of the key objectives of the report was to evaluate the existing market size, primary growth factors and opportunity within the exosome development and manufacturing services market in the mid to long term. Our year-wise projections of the current and future opportunity within the exosome development and manufacturing services market have further been segmented across [A] scale of operation (discovery / pre-clinical stage and clinical stage) [B] key geographies (North America, Europe, Asia-Pacific and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the anticipated industry’s growth.

The opinions and insights presented in the report were influenced by discussions held with several stakeholders in this domain.


The report features detailed transcripts of interviews held with the following individuals (in alphabetical order):


  • Jonathan Carson (Strategic Marketing Manager, EVerZom)
  • Navdeep Singh (Product Manager and Technical Lead, Clara Biotech)
  • Nicolas Rousseau (Chief Compliance Officer and Co-founder, RoosterBio)
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.


Key Questions Answered


  • Who are the leading players offering exosome related services?
  • Which are the various technology platforms available in the market for the development of exosomes?
  • What is the relative competitiveness of different exosome service providers?
  • What kind of partnership models are commonly adopted by industry and non-industry stakeholders?
  • What is the focus area of the ongoing research activities related to exosomes?
  • How has the intellectual property landscape of exosomes evolved over the years?
  • What are the key agenda items being discussed in various global events / conferences related to exosomes?
  • Which companies are actively involved in conducting clinical trials for exosomes?
  • How is the current and future market opportunity related to exosomes, likely to be distributed across key market segments?

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Types of Extracellular Vesicles
3.2.1. Apoptotic bodies: An Overview
3.2.2. Micro vesicles: An Overview
3.2.3. Exosomes: An Overview
3.3. Composition of Exosomes
3.4. Exosome Biogenesis
3.5 Exosome Development: An Overview
3.5.1. Methods for Isolation of Exosomes
3.5.2. Methods for Purification of Exosomes
3.5.3. Methods for Characterization of Exosomes
3.6. Manufacturing of Exosomes
3.7. Outsourcing of Exosomes related Services
3.8. Therapeutic Applications of Exosomes
3.8.1. Modification of Immune System
3.8.2. Exosomes as Targeted Drug Delivery Vehicles
3.8.3. Engineered Exosomes
3.9. Challenges Associated with the Development and Manufacturing of Exosomes
3.9.1. Lack of Standardized Isolation and Purification Methods
3.9.2. Limited Drug Loading Ability
3.9.3. Inadequate Clinical Grade Production
3.10. Future Perspectives
4. EXOSOME SERVICE PROVIDERS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Exosome Service Providers: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Location of Headquarters and Company Size
4.3. Analysis by Type of Service(s) Offered
4.3.1. Analysis by Method of Isolation
4.3.2. Analysis by Method of Purification
4.3.3. Analysis by Method of Characterization
4.3.4. Analysis by Method of Exosome Manufacturing
4.3.5. Analysis by Scale of Operation
4.3.6. Analysis by Scalability
5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Key Parameters
5.3. Scope and Methodology
5.4. Company Competitiveness Analysis: Exosome Service Providers in North America
5.5. Company Competitiveness Analysis: Exosome Service Providers in Europe
5.6. Company Competitiveness Analysis: Exosome Service Providers in Asia-Pacific and Rest of the World
6. COMPANY PROFILES: EXOSOME SERVICE PROVIDERS
6.1. Chapter Overview
6.2. Key Players based in North America
6.2.1. Creative Bioarray
6.2.1.1. Company Overview
6.2.1.2. Service Portfolio
6.2.1.3. Recent Developments and Future Outlook
6.2.2 Creative Biolabs
6.2.2.1 Company Overview
6.2.2.2 Service Portfolio
6.2.2.3 Recent Developments and Future Outlook
6.2.3. Creative Biostructure
6.2.3.1. Company Overview
6.2.3.2. Service Portfolio
6.2.3.3. Recent Developments and Future Outlook
6.3. Key Players based in Europe
6.3.1. Amsbio
6.3.1.1. Company Overview
6.3.1.2. Service Portfolio
6.3.1.3. Recent Developments and Future Outlook
6.3.2. Cambridge Bioscience
6.3.2.1. Company Overview
6.3.2.2. Service Portfolio
6.3.2.3. Recent Developments and Future Outlook
6.3.3. Lonza
6.3.3.1 Company Overview
6.3.3.2. Financial Information
6.3.3.3. Service Portfolio
6.3.3.4. Manufacturing Facilities
6.3.3.5. Recent Developments and Future Outlook
6.3.4. Qiagen
6.3.4.1. Company Overview
6.3.4.2. Financial Information
6.3.4.3. Service Portfolio
6.3.4.4. Recent Developments and Future Outlook
6.4. Key Players based in Asia-Pacific
6.4.1. Exopharm
6.4.1.1. Company Overview
6.4.1.2. Financial Information
6.4.1.3. Service Portfolio
6.4.1.4. Recent Developments and Future Outlook
6.4.2. Sumika Chemical Analysis Service
6.4.2.1. Company Overview
6.4.2.2. Service Portfolio
6.4.2.3. Recent Developments and Future Outlook
7. PARTNERSHIPS AND COLLABORATIONS
7.1. Chapter Overview
7.2. Partnership Models
7.3. Exosome Service Providers: List of Partnerships and Collaborations
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Year and Type of Partnership
7.3.4. Analysis by Type of Partner
7.3.5. Analysis by Type of Service Offered
7.3.6. Word Cloud Analysis: Emerging Focus Areas
7.3.7. Analysis by Target Disease Indication
7.3.8. Analysis by Therapeutic Area
7.3.9. Analysis by Type of Technology
7.3.10. Most Active Players: Analysis by Number of Partnerships
7.3.11. Analysis by Type of Service Offered and Type of Partnership
7.3.12. Analysis by Target Disease Indication and Type of Partnership
7.3.13. Regional Analysis
7.3.14. Intercontinental and Intracontinental Agreements
8. PUBLICATION ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.2.1. Analysis by Year of Publication
8.2.2. Analysis by Type of Service Offered
8.2.3. Word Cloud Analysis: Emerging Focus Areas
8.2.4. Popular Journals: Analysis by Number of Publications
8.2.5. Popular Journals: Analysis by Journal Impact Factor
9. GLOBAL EVENT ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. List of Global Events Related to Exosomes
9.3.1. Analysis by Year of Event
9.3.2. Analysis by Event Platform
9.3.3. Analysis by Type of Event
9.3.4. Analysis by Location of Event
9.3.5. Word Cloud: Evolutionary Trends in Event Agenda / Key Focus Area
9.3.6. Most Active Organizers: Analysis by Number of Events
9.3.7. Most Active Industry Participants: Analysis by Number of Events
9.3.8. Most Active Non-Industry Participants: Analysis by Number of Events
9.3.9. Analysis by Designation of Participant
9.3.10. Analysis by Affiliated Department of Participant
9.3.11. Most Active Speakers: Analysis by Number of Events
9.3.12. Geographical Mapping of Upcoming Events
10. EXOSOME BASED TECHNOLOGIES: MARKET OVERVIEW
10.1. Chapter Overview
10.2. Exosome Technologies: An Overview
10.3. List of Exosome Technology Providers
10.3.1. Exosome Technology Providers: Analysis by Year of Establishment
10.3.2. Exosome Technology Providers: Analysis by Company Size
10.3.3. Exosome Technology Providers: Analysis by Location of Headquarters
10.4 Exosome Technologies: Information of Technology Related Services and Therapeutic Applications
10.4.1 Summary
11. PATENT ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Exosomes Technologies: Patent Analysis
11.3.1. Analysis by Type of Patent
11.3.2. Analysis by Publication Year
11.3.3. Analysis by Application Year
11.3.4. Analysis by Geographical Location
11.3.5. Analysis by CPC Symbols
11.3.6. Word Cloud Analysis: Emerging Focus Areas
11.3.7. Analysis Type of Organization
11.3.8. Leading Industry Players: Analysis by Number of Patents
11.3.9. Leading Non-Industry Players: Analysis by Number of Patents
11.3.10. Leading Patent Assignees: Analysis by Number of Patents
11.4. Exosome Technologies: Patent Benchmarking Analysis
11.4.1. Analysis by Patent Characteristics (CPC Symbols)
11.5 Analysis of Patents by Age
11.6. Patent Valuation Analysis
11.7. Leading Patents by Number of Citations
12. CLINICAL TRIAL ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Analysis by Trial Status
12.4. Analysis by Trial Registration Year
12.5. Analysis by Trial Registration Year and Enrolled Patient Population
12.6. Analysis by Trial Recruitment Status
12.7. Analysis by Trial Phase and Number of Patients Enrolled
12.8. Analysis by Study Design
12.9. Analysis by Type of Sponsor / Collaborator
12.10. Leading Players: Analysis by Number of Registered Trials
12.11. Word Cloud Analysis: Emerging Focus Areas
12.12. Geographical Analysis by Number of Registered Trails
12.13. Geographical Analysis by Enrolled Patient Population
13. MARKET FORECAST
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Exosome Development and Manufacturing Services: Technology Licensing Model
13.4. Global Exosome Development and Manufacturing Services Market, 2022-2035
13.4.1. Global Exosome Development and Manufacturing Services Market: Distribution by Stage of Application, 2022 and 2035
13.4.1.1. Global Exosome Development and Manufacturing Services Market for Discovery / Preclinical Stage
13.4.1.2. Global Exosome Development and Manufacturing Services Market for Clinical Stage
13.4.3. Global Exosome Development and Manufacturing Services Market: Distribution by Region, 2022 and 2035
13.4.3.1. Exosome Development and Manufacturing Services Market in North America, 2022-2035
13.4.3.2. Exosome Development and Manufacturing Services Market in Europe, 2022-2035
13.4.3.3. Exosome Development and Manufacturing Services Market in Asia Pacific, 2022-2035
13.4.3.4. Exosome Development and Manufacturing Services Market in Rest of the World, 2022-2035
14. CONCLUDING REMARKS
15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. EVerZom
15.2.1. Company Snapshot
15.2.2. Interview Transcript: Nicolas Rousseau, Chief Compliance Officer and Cofounder
15.3. Clara Biotech
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Navdeep Singh, Product Manager and Technical Lead
15.4. RoosterBio
15.4.1. Company Snapshot
15.4.2. Interview Transcript: Jonathan Carson, Strategic Marketing Manager
16. APPENDIX 1: TABULATED DATA17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • 101 Bio
  • 10x Genomics
  • Aegle Therapeutics
  • Aethlon Medical 
  • AlfatestLab
  • American Association for the Advancement of Science (AAAS)
  • American Society for Bone and Mineral Research (ASBMR)
  • Amgen
  • AMSBIO
  • Anjarium Biosciences
  • Anopoli Biomedical Systems
  • Aruna Bio
  • ASN Events
  • Beth Israel Deaconess Medical Center
  • BioCat
  • BioPharma Asia
  • Biosyyd
  • BioTech Pharma Summit
  • Bio-Techne
  • BioXpedia
  • Broad Institute of MIT and Harvard
  • Cambridge Bioscience
  • Capital Biosciences 
  • Capricor Therapeutics
  • CD Bioparticles
  • Cell Guidance Systems
  • Cellex 
  • Cellular Biomedicine Group (CBMG)
  • Center for Biologics Evaluation and Research (CBER)
  • CHA Biotech
  • Ciloa 
  • Clara Biotech
  • Codiak BioSciences
  • Craif
  • Creative Bioarray
  • Creative Biolabs
  • Creative Biostructure
  • Creative Proteomics
  • Curexsys
  • David H. Murdock Research Institute (DHMRI)
  • Direct Biologics
  • Editas Medicine
  • EriVan Bio
  • European Society of Cardiology (ESC)
  • Esco Aster
  • EV Therapeutics 
  • Evercyte
  • EVerZom
  • Evox Therapeutics
  • Excilone
  • Excipio Technologies
  • EXIT071
  • ExoCoBio
  • Exogenus Therapeutics
  • Exolitus
  • ExoModTech
  • Exopharm
  • Exosome Diagnostics
  • Exosome Sciences (Acquired by Aethlon Medical)
  • Exosome Plus
  • Exosomics
  • ExoVectory
  • Finnish Red Cross
  • Florica Therapeutics
  • Frontage Laboratories
  • Fusion Conferences
  • GeneCopoeia
  • George Mason University
  • Goodwin Biotechnology
  • HansaBioMed Life Sciences (Acquired by Lonza)
  • Hanson Wade
  • Harvard University
  • Henry Ford Health System
  • ILIAS Biologics 
  • Immunostep
  • Innovex Therapeutics
  • Inscripta
  • Intezyne Technologies
  • Italian Association of Cell Culture (AICC)
  • Izasa Scientific
  • Izon Science
  • Jazz Pharmaceuticals
  • Kimera Labs
  • Lifeasible
  • Lonza
  • Luminous BioSciences 
  • Macrogen
  • Mahe Technologies
  • Mantra Bio
  • Marin Biologic Laboratories
  • Massachusetts General Hospital
  • Massachusetts Institute of Technology
  • MDimune
  • Merck
  • Miltenyi Biotec
  • Moderna
  • Nanovex Biotechnologies 
  • NanoView Biosciences
  • National Cancer Institute (NCI)
  • National Institute for Health and Medical Research (INSERM) (Acquired by Inserm Transfert)
  • National Taiwan University Hospital
  • NeuroDex
  • Norgen Biotek
  • Novus Biologicals (Acquired by Bio-Techne)
  • NurExone Biologic
  • Ocean Ridge Biosciences
  • Omnigene Medical technologies
  • OmniSpirant
  • OPTOLANE Technologies
  • Organicell Regenerative Medicine
  • Pathways to Stem Cell Science
  • Progenity
  • QIAGEN
  • Quantum Design
  • Ragon Institute of MGH, MIT and Harvard
  • Regeneron Pharmaceuticals
  • ReNeuron
  • RoosterBio
  • Ruijin Hospital
  • Sanford Burnham Prebys Medical Discovery Institute
  • Sarepta Therapeutics
  • System Biosciences (SBI)
  • SelectBIO
  • SMi Group
  • Spectradyne
  • Stanford University
  • Sumika Chemical Analysis Service
  • System Biosciences
  • Takeda
  • The Cell Factory 
  • University Medical Center Utrecht
  • University of Texas
  • Thermo Fisher Scientific
  • Thomas Jefferson University
  • Toray Industries
  • Tymora Analytical Operations
  • UCL Translational Research Office 
  • uFluidix
  • University Hospital Bonn (UKB)
  • Unicyte
  • University of California
  • University of Paris, France
  • Vanderbilt University
  • Vesigen Therapeutics
  • Vironova
  • VivaZome Therapeutics
  • Xollent Biotech
  • XOStem

Methodology

 

 

Loading
LOADING...